Microcin I47: Fighting Drug-Resistant Bacteria

**Technology Description:**

The innovation has been employed to combat drug-resistant bacteria, particularly within the *Enterobacteriaceae* family, utilizing the potency of microcin I47, an antimicrobial peptide. This unique molecule, delivered through probiotics or in purified form, effectively targets and eradicates drug resistant *Klebsiella* species and other resilient pathogens, offering a solution where conventional antibiotics fall short. The technology's wide-ranging applications extend to healthcare, where it transforms the treatment of drug-resistant infections, reduces healthcare costs, and mitigates hospital-acquired infections, benefiting vulnerable populations.

**Inventors:** Vanni Bucci

**Applications:**

- Infection and Treatment
- Autoimmune Diseases
- Cancer Therapy

**Benefits:**

- **Targeted Treatment:** Genetically engineered microorganisms can be designed to specifically target and combat pathogenic bacteria, offering highly precise and effective treatment.
- **Antibiotic Resistance Mitigation:** This technology can help address the growing problem of antibiotic resistance by providing alternative treatment options for infections.
- **Microbiome Restoration:** Genetically engineered microorganisms can be used to restore and balance the human microbiome, potentially improving gut health and overall well-being.

**Patent Status:** Patent Pending in USA and Europe


For more information: Catherine L. Ives, Ph.D.  
Office of Technology Commercialization and Ventures  
University of Massachusetts Dartmouth  
cives@umassd.edu